SEARCHSITE

ANGIO-SEAL FAMILY

MYDOCUMENTS

ANGIO-SEAL™ VASCULAR CLOSURE DEVICES

PRODUCT OVERVIEW

  • Designed for efficient and reliable vascular closure
  • Reducing complications and hospital stays for greater patient satisfaction1-6 
  • Increasing lab efficiencies so you can treat more patients5,7-11

Accessing the vascular system requires reliable hemostasis—the safety and recovery of your patients depends on it. Bleeding complications are associated with increased morbidity and mortality, longer hospitalization and a higher cost of care.1 Managing hemostasis can also place a burden on the efficiency of your lab. You need a faster, more reliable solution to help increase your ability to treat more patients, reduce nursing time and improve patient ambulation for earlier discharge.5

A more efficient alternative to manual compression, active closure devices help you achieve hemostasis much more rapidly and without added staff assistance.1-4 Our Angio-Seal vascular closure devices have been proven to help patients reach ambulation earlier, allowing them to be discharged sooner.5

Angio-Seal VIP
Angio-Seal STS
Angio-Seal EVOLUTION

REFERENCES

1. Marso, S. P., Amin, A.P., House, J. A., Kennedy, K. F., Spertus, J. A., Rao, S. V., ... Rumsfeld, J.S. (2010). Association between use of bleeding avoidance strategies and risk of periprocedural bleeding among patients undergoing percutaneous coronary intervention. Journal of the American Medical Association303(21), 2156-2164. http://dx.doi.org/10.1001/jama.2010.708
2. Resnic, F. S., Blake, G. J., Ohno-Machado, L., Selwyn, A. P., Popma, J. J., & Rogers, C. (2001). Vascular closure devices and the risk of vascular complications after percutaneous coronary intervention in patients receiving glycoprotein IIb-IIIa inhibitors. American Journal of Cardiology88(5), 493-496.  http://dx.doi.org/10.1016/S0002-9149(01)01725-8
3. Vaitkus, P.T. (2004). A meta-analysis of percutaneous vascular closure devices after diagnostic catheterization and percutaneous coronary intervention. Journal of Invasive Cardiology16(5), 243-246. http://www.medscape.com/viewarticle/479939_3
4. Arora, N., Matheny, M. E., Sepke, C., & Resnic, F. S. (2007). A propensity analysis of the risk of vascular complications after cardiac catheterization procedures with the use of vascular closure devices. American Heart Journal153(4), 606-611.  http://dx.doi.org/10.1016/j.ahj.2006.12.014
5. St. Jude Medical. Angio-Seal™ STS Plus, Angio-Seal™ VIP and Angio-Seal™ Evolution Instructions for Use.
6. Duffin, D. C., Muhlestein, J. B., Allisson, S. B., Horne, B. D., Fowles, R. E., Sorensen, S. G., ... Lappe, D. L. (2001). Femoral arterial puncture management after percutaneous coronary procedures: A comparison of clinical outcomes and patient satisfaction between manual compression and two different vascular closure devices. Journal of Invasive Cardiology13(5), 354-362. http://www.ncbi.nlm.nih.gov/pubmed/11385148
7. Moran, T. (2001). Increased throughput, staff efficiencies and patient comfort with the use of the Angio-Seal device. Cath Lab Digest, S, 16-18. http://www.cathlabdigest.com/
8. Patel, M., Kim, M., Karajgikar, R., Kodali, V., Kaplish, D., Lee, P., ... Kini, A. S. (2010). Outcomes of patients discharged the same day following percutaneous coronary intervention. Journal of the American College of Cardiology: Cardiovascular Interventions3(8), 851-858. http://dx.doi.org/10.1016/j.jcin.2010.05.010
9. Resnic, F. S., Arora, N., Matheny, M., & Reynolds, M. R. (2007). A cost-minimization analysis of the Angio-Seal vascular closure device following percutaneous coronary intervention (PCI). American Journal of Cardiology99(6), 766-770. http://dx.doi.org/10.1016/j.amjcard.2006.10.032
10. Copelen, K. (2000). Improving productivity with the Angio-Seal device. Cath Lab Digest, S, 4-6.
11. Holton, M. (2008). An ergonomic survey of cath lab repetitive stress injuries. Cath Lab Digest, 16(1). http://www.cathlabdigest.com/articles/An-Ergonomic-Survey-Cath-Lab-Repetitive-Stress-Injuries

Indications:

The  Angio-Seal Vascular Closure Device product family, including the STS Plus, VIP and Evolution platforms, is indicated for use in closing and reducing time to hemostasis of the femoral arterial puncture site in patients who have undergone diagnostic angiography procedures or interventional procedures using an 8 French or smaller procedural sheath for the 8 F Angio-Seal device and a 6 French or smaller procedural sheath for the 6 F Angio-Seal device. The Angio-Seal STS Plus, VIP and Evolution platform devices are also indicated for use to allow patients who have undergone diagnostic angiography to safely ambulate as soon as possible after sheath removal and device placement, as well as to allow patients who have undergone an interventional procedure to safely ambulate after sheath removal and device placement.

Important Safety Information:
Possible adverse events for vascular closure devices include, but are not limited to: bleeding or hematoma, AV fistula or pseudoaneurysm, infection, allergic reaction, foreign body reaction, inflammation or edema. This device should only be used by a licensed physician (or other health care professional authorized by or under the direction of such physician) possessing adequate instruction in the use of the device, e.g., participation in an Angio-Seal physician instruction program or equivalent.

RX ONLY. Refer to the product labels and package insert for complete warnings, precautions, potential complications, and instructions for use.